Asenapine: a novel psychopharmacologic agent with a unique human receptor signature (Q28270767)

0 references

G B Walker

0 references

S H Zorn

0 references

E H F Wong

Journal of Psychopharmacology

0 references

language of work or name

English

0 references

publication date

January 2009

0 references

published in

0 references

volume

0 references

issue

0 references

page(s)

65-73

0 references

cites work

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

A comparative review of new antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Functional, molecular and pharmacological advances in 5-HT7 receptor research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Dopamine D3 receptor antagonists as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Serotonergic basis of antipsychotic drug effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Pharmacological treatment strategies for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Metabolic risk during antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Current and novel approaches to the drug treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Cognition, schizophrenia and the effect of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107082944